Oligopeptide with melanin inhibition activity, tandem protein, composition and application thereof

By screening and modifying the gloproteinase solution products, it was found that the oligopeptide with the characteristic sequence NL significantly inhibited melanin production, solving the problem of skin activity of gloproteinase solution products in the prior art, achieving melanin inhibition and whitening effects, and having a wide range of cosmetics and pharmaceutical applications.

CN119019489APending Publication Date: 2024-11-26OSMUN BIOLOGICAL CO LTD

Patent Information

Application Number
CN202411160242.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art is difficult to clarify which substance in the gloproteinase product brings specific skin activities such as skin whitening, and the research on melanin inhibition of active peptides is relatively limited.

Method used

An oligopeptide with melanin inhibition activity, including an oligopeptide composed of amino acid sequences of the characteristic sequence NL and its derivatives. By enzymatic treatment of pearl proteins, the oligopeptide with melanin inhibition effect was screened, and the tandem protein and Modified forms improve their activity.

Benefits of technology

These oligopeptides significantly inhibit melanin production, improve skin pigmentation, have whitening effects, and have application prospects in cosmetics, foods and drugs. They can promote the degradation of melanosomal membranes and improve cathepsin expression, significantly reduce melanin production rate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019489A_ABST
    Figure CN119019489A_ABST
Patent Text Reader

Abstract

The invention discloses oligopeptide with melanin inhibitory activity, tandem protein, composition and application thereof, and relates to the technical field of whitening. The oligopeptide comprises oligopeptides consisting of at least one of the following amino acid sequences: NL, NLP, NLPS, NLPSSP, NLF, YNLF, VLYNLF, YNLFTR, VLDYNLFTR, VLYNLFTR, YNLL and YNLLEDFK. The oligopeptide provided by the invention can promote the generation rate of melanin to be obviously reduced and inhibit the generation of melanin, and has the effect of preventing or improving skin pigmentation. Besides, the oligopeptide also has an effect of promoting melanin body membrane degradation and has an effect of promoting melanin degradation, so that the oligopeptide has a good application prospect in cosmetics, foods, medicines and other products for relieving or improving hyperpigmentation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of whitening, and in particular to oligopeptides, tandem proteins, compositions and applications thereof with melanin inhibitory activity. Background Art

[0002] Hyriopsis cumingii is the main species of freshwater pearl culture, accounting for more than 95% of the market. Deep-processed pearl products have long been reported to have significant skin activity, such as whitening, anti-wrinkle, anti-oxidation, and promoting wound healing. As a beauty raw material with a long history, the protein components of pearls play a vital role in the efficacy. The protein components in pearls can produce a series of active peptides with different functions after enzymatic hydrolysis. However, there are few reports that can clearly point out which substances in the pearl enzymatic hydrolysis products bring about its specific skin activity. In order to further clarify the skin activity efficacy mechanism of its enzymatic hydrolysis products, it is necessary to further clarify its ingredients and corresponding efficacy.

[0003] Patent CN202310790127.7 discloses an active peptide and an active peptide mutant with melanin inhibitory effect and its application. However, its oligopeptide sequence is MSLWGQ. In order to further screen out more active pearl protein hydrolysate and its derivatives, the present invention is specially proposed. Summary of the invention

[0004] The purpose of the present invention is to provide oligopeptides, tandem proteins, compositions and applications thereof with melanin inhibitory activity to solve the above technical problems.

[0005] The present invention is achieved in that:

[0006] In the first aspect, the present invention provides an oligopeptide with melanin inhibitory activity, which comprises an oligopeptide composed of at least one of the following amino acid sequences: NL, NLP, NLPS, NLPSSP, NLF, YNLF, VLYNLF, YNLFTR, VLDYNLFTR, VLYNLFTR, YNLL and YNLLEDFK, and the oligopeptide has a characteristic sequence: NL.

[0007] In a second aspect, the present invention provides an oligopeptide with melanin inhibitory activity, wherein the oligopeptide has a characteristic sequence: NL, and the amino acid sequence of the oligopeptide is a sequence obtained by a single amino acid mutation in any of the following amino acid sequences: NL, NLP, NLPS, NLPSSP, NLF, YNLF, VLYNLF, YNLFTR, VLDYNLFTR, VLYNLFTR, YNLL and YNLLEDFK.

[0008] In a third aspect, the present invention provides an oligopeptide with melanin inhibitory activity, the oligopeptide having a characteristic sequence: NL, the oligopeptide comprising an oligopeptide composed of at least one of the following amino acid sequences, and at least one amino acid in the oligopeptide is modified: NL, NLP, NLPS, NLPSSP, NLF, YNLF, VLYNLF, YNLFTR, VLDYNLFTR, VLYNLFTR, YNLL and YNLLEDFK.

[0009] In a fourth aspect, the present invention provides a tandem protein, the amino acid sequence of which is formed by repeated tandem connection of n active oligopeptides, wherein n is a natural number greater than 1, and the oligopeptide is the oligopeptide with melanin inhibitory activity shown above.

[0010] In a fifth aspect, the present invention provides the use of an oligopeptide with melanin inhibitory activity or the above-mentioned tandem protein in the preparation of a melanin production inhibitory product.

[0011] In a sixth aspect, the present invention provides the use of an oligopeptide with melanin inhibitory activity or the above-mentioned tandem protein in the preparation of a product for degrading melanosome membranes.

[0012] In a seventh aspect, the present invention provides the use of an oligopeptide with melanin inhibitory activity or the above-mentioned tandem protein in the preparation of a product that promotes melanin degradation.

[0013] In an eighth aspect, the present invention provides the use of an oligopeptide with melanin inhibitory activity or the above-mentioned tandem protein in the preparation of a product for preventing, alleviating or improving pigmentation.

[0014] In a ninth aspect, the present invention provides a composition comprising the active ingredient of any one of (1) and (2):

[0015] (1) comprising the above-mentioned oligopeptide with melanin inhibitory activity or the above-mentioned tandem protein;

[0016] (2) An oligopeptide having the above-mentioned melanin inhibitory activity or the above-mentioned tandem protein.

[0017] The present invention has the following beneficial effects:

[0018] (1) The present invention performs proteolysis on pearls with whitening activity, and after separation and analysis of the enzymatic hydrolysis products and efficacy verification, it is found that a variety of oligopeptides with specific amino acid sequences have the effect of inhibiting melanin production. Therefore, these oligopeptides also have the effect of improving skin pigmentation or whitening. The above oligopeptides all have a characteristic sequence: NL, which makes the oligopeptides have whitening activity.

[0019] (2) After a single amino acid mutation is performed on the amino acid sequence of any oligopeptide except the characteristic sequence, the obtained oligopeptide still has the inhibitory effect on melanin production.

[0020] (3) After the amino acids of the oligopeptide are modified, the modified oligopeptide can significantly reduce the melanin production rate and inhibit the production of melanin. Therefore, the modified oligopeptide has the effect of preventing or improving skin pigmentation.

[0021] (4) The oligopeptides provided by the present invention have a promoting effect on the degradation of melanosome membranes. The addition of oligopeptides increases the expression level of tissue proteases, thereby accelerating the hydrolysis of melanosome membrane proteins, accelerating the autophagy level of human epidermal keratinocytes, and further accelerating the degradation of melanosome membranes. In addition, the oligopeptides can promote the expression of tissue proteases in a concentration-dependent manner. Therefore, the oligopeptides have the effect of preventing or improving skin pigmentation.

[0022] (5) The oligopeptide provided by the present invention has the effect of promoting the degradation of melanin and has good application prospects in cosmetics, foods, medicines and other products that alleviate or improve pigmentation. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0024] Figure 1 This is a graph showing the CCK8 experimental results of oligopeptide NLP. DETAILED DESCRIPTION

[0025] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.

[0026] The term "peptide" is used herein in its conventional sense, i.e., a polymer with amino acids as monomers and connected by amide bonds, which can also be called a polypeptide. When the amino acid is an α-amino acid, the L-optical isomer or the D-optical isomer can be used. In addition, non-natural amino acids such as β-alanine, phenylglycine and homoarginine are also included. The length of the peptide of the present invention is three or more amino acid monomers, and can be as long as 20 to 50 amino acid monomers. The standard abbreviations of amino acids are used (as described below).

[0027] The common one-letter and three-letter codes for amino acids are used herein as follows:

[0028] A(Ala) alanine C(Cys) cysteine ​​D(Asp) aspartic acid;

[0029] E(Glu) Glutamate F(Phe) Phenylalanine G(Gly) Glycine;

[0030] H (His) histidine I (Ile) isoleucine K (Lys) lysine;

[0031] L(Leu) Leucine M(Met) Methionine N(Asn) Asparagine;

[0032] P(Pro) Proline Q(Gln) Glutamine R(Arg) Arginine;

[0033] S (Ser) serine T (Thr) threonine V (Val) valine;

[0034] W (Trp) tryptophan Y (Tyr) tyrosine.

[0035] In the first aspect, the present invention provides an oligopeptide with melanin inhibitory activity, which comprises an oligopeptide composed of at least one of the following amino acid sequences: NL, NLP, NLPS, NLPSSP, NLF, YNLF, VLYNLF, YNLFTR, VLDYNLFTR, VLYNLFTR, YNLL and YNLLEDFK, and the oligopeptide has a characteristic sequence: NL.

[0036] In a preferred embodiment of the present invention, the oligopeptide has any one of the following characteristic sequences: NLP, NLF, YNL and YNLF.

[0037] The characteristic sequence in the present invention refers to: a common sequence or core sequence that all oligopeptides have. The inventors have found that the above oligopeptides all have the characteristic sequence: NL, which makes the oligopeptides have melanin inhibitory activity. In other embodiments, the oligopeptides may also have the characteristic sequence NLP, NLF, YNL or YNLF. As long as the oligopeptides have the above characteristic sequence, they all fall within the protection scope of the present invention.

[0038] The present invention performs proteolysis on pearls with whitening activity, and after separation and analysis of the enzymatic hydrolysis products and efficacy verification, it is found that a variety of oligopeptides with the above amino acid sequences have the effect of inhibiting melanin production. Therefore, these oligopeptides also have the effect of improving skin pigmentation or whitening.

[0039] For the purposes of the present invention, "oligopeptide" refers to a peptide based on 2-9 amino acids, in particular a peptide based on 3-9 amino acids, and in particular a peptide based on 4-9 amino acids, preferably any linear peptide of 2-9 amino acids, more preferably a linear peptide of 3-9 or 4-9 amino acids.

[0040] In one embodiment, the oligopeptide is a mixture of oligopeptides composed of the above-mentioned multiple amino acid sequences, such as a combination of NLP and NLPS, or a combination of YNLFTR, VLDYNLFTR, VLYNLFTR, YNLL and YNLLEDFK. Those skilled in the art can easily make any combination as needed.

[0041] In a preferred embodiment of the present invention, the oligopeptide comprises at least one of the following amino acid sequences: NL, NLPS, NLPSSP, YNLL, YNLLEDFK. Compared with other oligopeptides, these oligopeptides have a better melanin production inhibition effect and a more significant effect of alleviating or improving skin pigmentation.

[0042] In a second aspect, the present invention provides an oligopeptide with melanin inhibitory activity, wherein the oligopeptide has a characteristic sequence: NL, and the amino acid sequence of the oligopeptide is a sequence obtained by subjecting any of the following amino acid sequences to a single amino acid mutation: NL, NLP, NLPS, NLPSSP, NLF, YNLF, VLYNLF, YNLFTR, VLDYNLFTR, VLYNLFTR, YNLL and YNLLEDFK;

[0043] That is, in any of the above amino acid sequences, except NL, one of the remaining amino acids is a variable amino acid, which can mutate into any of the other 19 natural amino acids. The 20 natural amino acids are: alanine, valine, leucine, isoleucine, methionine, aspartic acid, glutamic acid, lysine, arginine, glycine, serine, threonine, cysteine, asparagine, glutamine, phenylalanine, tyrosine, tryptophan, histidine, and proline.

[0044] The inventors have found that after a single amino acid mutation is performed on the amino acid sequence of any oligopeptide except the characteristic sequence, the obtained oligopeptide still has the inhibitory effect of melanin production, so these oligopeptides also have the effect of improving skin pigmentation or whitening. It is easy for those skilled in the art to think that the mutated oligopeptides all have characteristic sequences or core sequences and have corresponding whitening activity. For example, oligopeptides NLPSSA, NLPSSC, NLPSSD, NLPSSE, NLPSSG and NLPSSH.

[0045] In a preferred embodiment of the present invention, the oligopeptide has any one of the following characteristic sequences: NLP, NLF, YNL and YNLF;

[0046] In a preferred embodiment of the present invention, the oligopeptide comprises at least one of the following amino acid sequences: NL, NLPS, NLPSSP, YNLL, YNLLEDFK. Compared with other oligopeptides, these three oligopeptides have a better melanin production inhibition effect and a more significant effect of improving skin pigmentation.

[0047] In a third aspect, the present invention provides an oligopeptide with melanin inhibitory activity, the oligopeptide having a characteristic sequence: NL, the oligopeptide comprising an oligopeptide composed of at least one of the following amino acid sequences, and at least one amino acid in the oligopeptide is modified: NL, NLP, NLPS, NLPSSP, NLF, YNLF, VLYNLF, YNLFTR, VLDYNLFTR, VLYNLFTR, YNLL and YNLLEDFK;

[0048] In a preferred embodiment of the present invention, the oligopeptide has any one of the following characteristic sequences: NLP, NLF, YNL and YNLF;

[0049] In a preferred embodiment of the present invention, the oligopeptide comprises an oligopeptide composed of at least one of the following amino acid sequences: NL, NLPS, NLPSSP, YNLL, YNLLEDFK;

[0050] In a preferred embodiment of the present invention, the modification is selected from at least one of glycosylation modification, phosphorylation modification, ubiquitination modification, S-nitrosylation modification, methylation modification, hydroxylation modification and acylation modification.

[0051] Phosphorylation modification occurs, for example, on serine (S) residues. Methylation modification occurs, for example, on lysine (K) residues. Ubiquitination modification occurs, for example, on lysine (K) residues; and hydroxylation modification occurs, for example, on proline (P) and / or lysine (K) residues.

[0052] In a preferred embodiment of the present invention, the methylation modification is selected from at least one of N-methylation modification and O-methylation modification;

[0053] In a preferred embodiment of the present invention, the acylation modification is selected from at least one of acetylation modification, amidation modification, nicotinoylation modification, palmitoylation modification, succinylation modification, acryloylation modification and myristoylation modification;

[0054] In a preferred embodiment of the present invention, the acylation modification is selected from at least one of N-terminal nicotinoylation modification, N-acetylation modification, N-palmitoylation modification, N-succinylation modification, N-myristoylation modification and C-amidation modification.

[0055] The effects of the above modifications include but are not limited to improving the stability of the oligopeptide.

[0056] In a fourth aspect, the present invention provides a tandem protein, wherein the amino acid sequence of the tandem protein is formed by repeated tandem connection of n active oligopeptides, wherein n is a natural number greater than 1, and the oligopeptide is the above-mentioned oligopeptide with melanin inhibitory activity;

[0057] It is easy for those skilled in the art to think that when an oligopeptide has whitening activity, its tandem protein usually also has a corresponding function.

[0058] In a preferred embodiment of the present invention, n is selected from any value between 2 and 5. For example, n is 1, 2, 3, 4 or 5.

[0059] In a fifth aspect, the present invention provides an oligopeptide with melanin inhibitory activity or the above-mentioned tandem protein for use in the preparation of a melanin production inhibitory product. The melanin production inhibitory product includes but is not limited to a melanin inhibitor, a whitening and freckle removal mask, a whitening and moisturizing essence, an eye or facial freckle removal essence, a whitening cream, and a medical dressing, wherein the melanin inhibitor is at least one of a whitening agent and / or a freckle removal agent.

[0060] In a sixth aspect, the present invention provides the use of an oligopeptide with melanin inhibitory activity or the above-mentioned tandem protein in the preparation of a product for degrading melanosome membranes;

[0061] In a preferred embodiment of the present invention, the application of degrading melanosome membranes includes at least one of the following application modes:

[0062] (1) Increase the expression level of cathepsin;

[0063] (2) Accelerate autophagy of human epidermal keratinocytes.

[0064] Cathepsin is an intracellular protease that mainly exists in lysosomes and participates in the hydrolysis of proteins. By increasing the expression level of cathepsin, it helps to improve the ability to degrade melanosome membrane proteins, thereby accelerating the degradation of melanosome membranes. It accelerates the autophagy of human epidermal keratinocytes. The increase in the level of autophagy helps the lysosomes of human epidermal keratinocytes to degrade the melanosome membranes.

[0065] Products that degrade melanosome membranes include, but are not limited to, topical, oral, or injectable preparations, topical preparations acceptable to dermatology, and injectable preparations selected from powder injections or water injections.

[0066] the term" Dermatologically acceptable "In this context, it is meant that the compositions and ingredients are suitable for use in contact with mammalian keratinous tissue without causing excessive toxicity, incompatibility, instability, allergic response, etc.

[0067] In a seventh aspect, the present invention provides the use of an oligopeptide with melanin inhibitory activity or the above-mentioned tandem protein in the preparation of a product that promotes melanin degradation.

[0068] The oligopeptides or tandem proteins provided by the present invention contribute to significantly improving the degradation rate of melanin in human keratinocytes, indicating that they promote the degradation of melanin in human keratinocytes. Therefore, the oligopeptides have the effect of preventing or improving skin pigmentation. However, the oligopeptides currently having the effect of inhibiting melanin production (such as hexapeptide-2 (amino acid sequence is HWAWFK), nonapeptide-1 (amino acid sequence MPFRWFKPV)) do not show the effect of promoting melanin degradation.

[0069] Phosphorylation modification occurs, for example, on serine (S) residues. Methylation modification occurs, for example, on lysine (K) residues. Ubiquitination modification occurs, for example, on lysine (K) residues; and hydroxylation modification occurs, for example, on proline (P) and / or lysine (K) residues.

[0070] In a preferred embodiment of the present invention, the methylation modification is selected from at least one of N-methylation modification and O-methylation modification;

[0071] In a preferred embodiment of the present invention, the acylation modification is selected from at least one of acetylation modification, amidation modification, palmitoylation modification, succinylation modification, acryloylation modification and myristoylation modification;

[0072] In a preferred embodiment of the present invention, the acylation modification is selected from at least one of N-acetylation modification, N-palmitoylation modification, N-succinylation modification, N-myristoylation modification and C-amidation modification.

[0073] Products that promote melanin degradation include but are not limited to melanin inhibitors, whitening and freckle removal masks, whitening and moisturizing essences, eye or facial freckle removal essences, whitening creams, and medical dressings. The melanin inhibitor is at least one of the whitening agents and / or freckle removal agents.

[0074] In an eighth aspect, the present invention provides the use of an oligopeptide with melanin inhibitory activity or the above-mentioned tandem protein in the preparation of a product for preventing, alleviating or improving pigmentation.

[0075] In a preferred embodiment of the present invention, the product is a medicine, a cosmetic, a skin care product or a food.

[0076] The dosage form of the drug is selected from: injection, syrup, elixir, suspension, powder, granule, tablet, capsule, lozenge, cream, ointment, gel or emulsion.

[0077] Food includes but is not limited to health food, flour products, beverages, dairy products, etc.

[0078] The cosmetics are selected from: bath gel, essence, original liquid, essence milk, moisturizing cream, foundation cream, concealer, essence cream or primer.

[0079] The skin care products are selected from any one of skin care water, lotion, face cream, neck cream, face mask, neck mask, essence, eye cream, sunscreen, massage oil, makeup remover, makeup remover oil, makeup powder products, shampoo, conditioner, and shower gel. The skin care products include but are not limited to one or more of whitening skin care products, brightening skin care products, and yellowing skin care products.

[0080] In a ninth aspect, the present invention provides a composition comprising the active ingredient of any one of (1) and (2):

[0081] (1) comprising the above-mentioned oligopeptide with melanin inhibitory activity or the above-mentioned tandem protein;

[0082] (2) comprising the above-mentioned oligopeptide with melanin inhibitory activity or the above-mentioned tandem protein;

[0083] In a preferred embodiment of the present invention, the content of the active ingredient in the composition is 0.01-100 ppm; the content of the active ingredient in the composition is, for example, 0.01 ppm, 0.02 ppm, 0.05 ppm, 0.08 ppm, 0.1 ppm, 0.15 ppm, 0.2 ppm, 0.5 ppm, 1 ppm, 10 ppm 100 ppm, or any one of 0.01-10 ppm, or 0.1-5 ppm, or 1-10 ppm, or 5-100 ppm.

[0084] In a preferred embodiment of the present invention, the content of the active ingredient in the composition is 1-100 ppm; at this content, the composition has a better effect of promoting melanin degradation.

[0085] In a preferred embodiment of the present invention, the composition further comprises auxiliary materials.

[0086] The dosage form of the composition is selected from essence, powder, emulsion, cream, gel, facial mask and dressing.

[0087] In an optional embodiment, the composition product is selected from a whitening and anti-freckle mask, a whitening and moisturizing essence, an eye or facial anti-freckle essence, a whitening cream, and a medical dressing.

[0088] The oligopeptides of the present invention may be further formulated with other ingredients that can be used to treat or relieve skin symptoms or with ingredients that can reduce the irritation of the peptide when used in conjunction with abrasive procedures. Examples of these additional ingredients are referred to herein as " Treatment agent”, including 1% vitamin K and 1% hydrocortisone in an aqueous base; acne treatment formulations (e.g., salicylic acid, alcohol base buffered by witchhaze); fine lines / wrinkle treatment formulations (e.g., water-based hyaluronic acid); hydrating formulations (e.g., mineral oil-based calendula, vitamin A, D or E, or any combination thereof); antioxidant formulations / free radical scavengers (e.g., mineral oil-based vitamins A, E and K). Other examples of product types that can be used alone or in combination with other compounds (or excipients) include preservatives, astringents, cleansers, pore decongestants, balms, botanicals, collagen stimulators, herbs, microemulsifiers, oxygen delivery vehicles, proteins, serums, skin firming agents, The products that can be named are (with the beneficial effects in parentheses): aloe vera (calming); alpha hydroxy acids (peel); alpha lipoic acid (antioxidant); benzoyl peroxide (benzoil) and other peroxides (acne); ceramides (hydrator); copper (toning); copper peptides (toning); CoQ-10 (coenzyme Q -10) and other enzymes (toning); cortisone (calming); glycolic acid (peel); hyaluronic acid (collagen activation); hydrolipid (hydrator); lactic acid (peel); magnesium ascorbyl phosphate (free radical scavenger, collagen stimulator, bleaching); niacin (vasodilation); phospholipids (moisturizing); potassium (toning, psoriasis) and salicylic acid (acne).

[0089] As other treatment agents, the oligopeptides and preparations of the present invention can also be optionally mixed with each other and with other skin whitening agents for treatment purposes (i.e., skin whitening or whitening). For example, combinable skin whitening products include, but are not limited to, cysteine, 4-thioresorcinol, 3-aminotyrosine, 5-hydroxy-2-hydroxymethyl-γ-pyridone, fomesjaponicus and ganoderma lucidum extracts, kojic acid, glabridin, licorice extract, glycyrrhizic acid, catharanthus roseus extract, proteoglycans, protease inhibitors, other oligopeptides, betaine, and 4-benzyloxy-2-hydroxybenzoic acid methyl ester, 4-benzyloxy-2-hydroxybenzoic acid, etc. The oligopeptides of the present invention may also be combined or combined with other tyrosinase inhibitors, such as isoliquiritigenin chalcone (ILC) or 4,4'-dihydroxybiphenyl (44'-BP).

[0090] When the composition is a medicine, it also includes pharmaceutically acceptable excipients.

[0091] In a preferred embodiment of the present invention, the pharmaceutically acceptable excipient is selected from at least one of a filler, a disintegrant, a lubricant, a flavoring agent, a binder, a suspending agent and a flavor.

[0092] Pharmaceutically acceptable excipients include but are not limited to: pharmaceutically acceptable carriers, auxiliary substances or solvents. Pharmaceutically acceptable excipients include various organic or inorganic carriers and / or auxiliary materials because they are commonly used for pharmaceutical purposes, especially for solid pharmaceutical preparations. Examples include: excipients, such as sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate; binders, such as cellulose, methylcellulose, hydroxypropyl cellulose, polypropyl pyrrolidone, gelatin, gum arabic, polyethylene glycol, sucrose, starch; disintegrants, such as starch, hydrolyzed starch, carboxymethyl cellulose, carboxymethyl cellulose calcium salt, hydroxypropyl starch, ethylene glycol starch sodium, sodium bicarbonate, calcium phosphate, calcium citrate; lubricants, such as magnesium stearate, talc, sodium lauryl sulfate; flavors, such as citric acid, menthol, glycine , orange powder; preservatives, such as sodium benzoate, sodium bisulfite, parabens (such as methyl paraben, ethyl paraben, propyl paraben, butyl paraben); stabilizers, such as citric acid, sodium citrate, acetic acid and polycarboxylic acids from the titriplex series, such as diethylenetriaminepentaacetic acid (DTPA); suspending agents, such as methylcellulose, polyvinylpyrrolidone, aluminum stearate; dispersants; diluents, such as water, organic solvents; waxes, fats and oils, such as beeswax, cocoa butter; polyethylene glycol; white petrolatum, etc.

[0093] In a preferred embodiment of the present invention, the dosage form of the drug is tablets, pills, powders, suspensions, gels, emulsions, creams, granules, nanoparticles, capsules, suppositories, injections or sprays.

[0094] In an optional embodiment, the above-mentioned medicine is a liquid pharmaceutical preparation (such as a kind of injection), such as solution, suspension and gel usually contain liquid carrier, such as water and / or pharmaceutically acceptable organic solvent. In addition, such liquid preparations may also include pH adjusting agents, emulsifiers or dispersants, buffers, preservatives, wetting agents, gelling agents (such as methylcellulose), dyes and / or flavoring agents, such as defined above. The medicine may be isotonic, that is, they may have the same osmotic pressure as blood. The isotonicity of the medicine may be regulated by using sodium chloride and other pharmaceutically acceptable agents, such as glucose, maltose, boric acid, sodium tartrate, propylene glycol and other inorganic or organic soluble substances. The viscosity of the liquid composition may be regulated by pharmaceutically acceptable thickeners such as methylcellulose. Other suitable thickeners include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, etc. The preferred concentration of the thickener depends on the selected agent.

[0095] In a preferred embodiment of the present invention, the drug is formulated for oral administration or injection.

[0096] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.

[0097] Example 1

[0098] Pearl polypeptide sequence structure identification: Submicron pearl powder was acid-hydrolyzed to obtain pearl protein, and then enzymatically hydrolyzed with neutral protease, separated by ultrafiltration, concentrated by nanofiltration, and freeze-dried to obtain pearl polypeptide composition. The pearl polypeptide composition was subjected to peptide group identification and analysis. The identification and analysis method was as follows: 4 μl of total peptide was separated by NANO-UPLC liquid phase system EASY-nLC 1200 and then connected to a mass spectrometer (Q-Exactive HFX) equipped with a nanoliter ion source for data acquisition. Chromatographic separation was performed using a 100 μm ID×15 cm reverse phase column (Reprosil-Pur 120C18-AQ 1.9 μm, Dr. Maisch). The mobile phase used an acetonitrile-water-formic acid system, wherein mobile phase A was 0.1% formic acid-98% aqueous solution (acetonitrile was 2%), and phase B was 0.1% formic acid-80% acetonitrile solution (water was 20%). After the chromatographic column was equilibrated with 100% phase A, the sample was directly loaded onto the chromatographic column by an autosampler and then separated by a chromatographic column gradient with a flow rate of 300 nL / min and a gradient time of 60 min. The proportion of mobile phase B was 2-5% for 2 min, 5% to 22% for 34 min, 22% to 45% for 20 min, 45% to 95% for 2 min, and 95% for 2 min. The mass spectrometry analysis used the data-dependent acquisition (DDA) mode, with a total analysis time of 60 min and a positive ion detection mode. The primary scan (Full scan) range was 350 to 1600 m / z, the resolution was 120k (@200 m / z), the AGC was 1E6, and the maximum ion injection time (max IT) was 50 ms; the 20 ions with the highest intensity (top 20) in the primary scan were screened by the quadrupole and then fragmented using HCD for fragment ion scanning. The quadrupole isolation window was 1.2 m / z, the normalized collision energy (NCE) was 30%, the AGC was 1E5, and the max IT was 100 ms. The secondary scan resolution was 15k. The dynamic exclusion time was set to 30 s according to the chromatographic peak width; single-charged and >6-valent ions were not subjected to secondary scanning. The raw data files were searched and analyzed using Proteome Discoverer software (PD) (version 2.4.0.305, Thermo Fisher Scientific) and the built-in Sequest HT search engine.

[0099] The identification results include NL, NLP, NLPS, and NLPSSP. The peptide sequence is from the plasma membrane calcium ion ATPase in pearl protein. Its amino acid sequence is shown in SEQ ID NO.1, as follows:

[0100]

[0101] The identification results include NLF, YNLF, VLYNLF, YNLFTR, and VLYNLFTR. The peptide sequence is from the silk matrix protein in the pearl protein, and its amino acid sequence is shown in SEQ ID NO.2, as follows:

[0102] .

[0103] After remodeling the above polypeptides, YNLL and YNLLEDFK were obtained.

[0104] Example 2

[0105] This embodiment provides an active oligopeptide, whose amino acid sequence is NL.

[0106] Example 3

[0107] This embodiment provides an active oligopeptide, whose amino acid sequence is NLP.

[0108] Example 4

[0109] This embodiment provides an active oligopeptide, whose amino acid sequence is NLPS.

[0110] Example 5

[0111] This embodiment provides an active oligopeptide, whose amino acid sequence is NLPSSP.

[0112] Example 6

[0113] This example provides an active oligopeptide, whose amino acid sequence is NLF.

[0114] Example 7

[0115] This example provides an active oligopeptide, whose amino acid sequence is YNLF.

[0116] Example 8

[0117] This example provides an active oligopeptide, whose amino acid sequence is VLYNLF.

[0118] Example 9

[0119] This example provides an active oligopeptide, whose amino acid sequence is YNLFTR.

[0120] Example 10

[0121] This embodiment provides an active oligopeptide, whose amino acid sequence is VLDYNLFTR.

[0122] Embodiment 11

[0123] This embodiment provides an active oligopeptide, whose amino acid sequence is VLYNLFTR.

[0124] Example 12

[0125] This example provides an active oligopeptide, whose amino acid sequence is YNLL.

[0126] Example 13

[0127] This embodiment provides an active oligopeptide, whose amino acid sequence is YNLLEDFK.

[0128] Embodiment 14

[0129] This embodiment provides an active oligopeptide, whose amino acid sequence is NLPSSP, and whose N-terminus is acetylated, and is an N-terminal acetylated modification product.

[0130] Embodiment 15

[0131] This embodiment provides an active oligopeptide, whose amino acid sequence is NLPSSP, and whose N-terminus is succinylated, which is an N-terminal succinylated modified product.

[0132] Example 16

[0133] This embodiment provides an active oligopeptide, whose amino acid sequence is NLPSSP, and whose N-terminus is palmitoylated, and is an N-terminal palmitoylated modified product.

[0134] Embodiment 17

[0135] This example provides an active oligopeptide (after mutation), whose amino acid sequence is NLPSSA.

[0136] Embodiment 18

[0137] This example provides an active oligopeptide (after mutation), whose amino acid sequence is NLPSSC.

[0138] Embodiment 19

[0139] This example provides an active oligopeptide (after mutation), the amino acid sequence of which is NLPSSD.

[0140] Embodiment 20

[0141] This example provides an active oligopeptide (after mutation), whose amino acid sequence is NLPSSE.

[0142] Embodiment 21

[0143] This example provides an active oligopeptide (after mutation), the amino acid sequence of which is NLPSSG.

[0144] Embodiment 22

[0145] This example provides an active oligopeptide (after mutation), whose amino acid sequence is NLPSSH.

[0146] Comparative Example 1

[0147] The oligopeptide is nonapeptide-1, and its amino acid sequence is MPFRWFKPV.

[0148] Comparative Example 2

[0149] The oligopeptide is hexapeptide-2, and its amino acid sequence is HWAWFK.

[0150] Experimental Example 1

[0151] Effect of oligopeptides on B16 melanoma cell viability and inhibition of melanin production:

[0152] B16 melanoma cells in good growth state were inoculated on a 96-well plate at a concentration of 10,000 cells / well (using Gibco's DMEM high-glucose medium). After 24 hours, a blank group (medium) or a sample to be tested was added to a final concentration of 1ppm, 10ppm, and 100ppm, and then further cultured at 37°C for 48 hours. 10μL / well Cell Counting Kit-8 (purchased from Beyotime Biotechnology) was added to the 96-well plate. The absorbance at 450nm after 0 minutes and 120 minutes was measured using an ELISA reader, and the value of Δ2 hours was used as the cell number. In this method, the tetrazolium salt WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazoli um, monosodium salt] that produces highly sensitive water-soluble formazan is reduced by intracellular dehydrogenases, and the number of living cells is measured by measuring the absorbance of the produced water-soluble formazan at 450nm, thereby determining the safe action concentration range of the oligopeptide.

[0153] Figure 1 The cell viability statistics of oligopeptide NLP in the concentration range of 0100ppm are shown in the figure. The results show that the oligopeptide has no toxicity to B16 melanoma cells in the concentration range of 0100ppm. The unit of ppm is mg / L.

[0154] B16 melanoma cells with good growth status were inoculated on a 6-well plate at a concentration of 300,000 cells / well (using Gibco's DMEM high-glucose medium). After 24 hours, a blank control group (culture medium), a positive control group nonapeptide-1 and hexapeptide-2, or a sample to be tested were added to make the final concentration 1 ppm, and then further cultured at 37°C for 48 hours, washed with PBS three times, and then 1 mL of 1 mol / L NaOH was added. After incubation at 60°C for 60 minutes, the OD value at 450nm was detected, and the inhibitory effect of the oligopeptide on melanin production was calculated according to the following formula:

[0155] Melanin synthesis inhibition rate = [1-(sample group OD 450nm / cell number) / (blank group OD 450nm / cell number)]×100%

[0156] The principle of the NaOH cleavage method is based on the strong alkaline properties of NaOH, which chemically cleaves or denatures melanin to promote its dissolution.

[0157] The results of the melanin production inhibition effect of oligopeptides are shown in the following table:

[0158] Examples and Comparative Examples Amino acid sequence Melanin production inhibition rate (%) Example 2 NL 26.67** Example 3 NLP 17.13* Example 4 NLPS 29.79** Example 5 NLPSSP 29.39** Example 6 NLF 25.19** Example 7 YNLF 19.10** Example 8 VLYNLF 19.18** Example 9 YNLFTR 23.36** Example 10 VLDYNLFTR 15.15* Embodiment 11 VLYNLFTR 23.74** Example 12 YNLL 27.30** Example 13 YNLLEDFK 26.78** Comparative Example 1 Nonapeptide-1 23.02** Comparative Example 2 Hexapeptide-2 24.98**

[0159] *: p<0.05, **: p<0.01.

[0160] Compared with the blank control group, oligopeptides NL, NLP, NLPS, NLPSSP, NLF, YNLF, VLYNLF, YNLFTR, VLDYNLFTR, VLYNLFTR, YNLL, and YNLLEDFK can significantly inhibit the melanin production in B16 melanoma cells, and NL, NLPS, NLPSSP, YNLL, and YNLLEDFK are more effective than the positive control oligopeptides (nonapeptide-1 and hexapeptide-2) known to have melanin production inhibitory effects. Therefore, it can be considered that these oligopeptides have the effect of improving skin pigmentation.

[0161] The above results show that 1 ppm of oligopeptides have the effect of inhibiting melanin production, and NL, NLPS, NLPSSP, YNLL, and YNLLEDFK oligopeptides are more effective than the positive control oligopeptides (nonapeptide-1 and hexapeptide-2). Therefore, these oligopeptides have the effect of improving skin pigmentation.

[0162] Experimental Example 2

[0163] This experimental example tests the effective concentration of the oligopeptide's melanin production inhibition effect:

[0164] B16 melanoma cells in good growth condition were seeded on a 6-well plate at a concentration of 300,000 cells / well (using Gibco's DMEM high-glucose medium). After 24 hours, a blank control group (culture medium), a positive control group hexapeptide-2, nonapeptide-1 (final concentration 100 ppm), or LEF with a final concentration of 0.01, 0.1, 1, 10 or 100 ppm were added, and then further cultured at 37°C for 48 hours. The NaOH cleavage method was used to detect the inhibitory effect of the oligopeptides on melanin production. The results are shown in the following table.

[0165] Melanin production inhibition effect of oligopeptides at different concentrations

[0166] Oligopeptide concentration (ppm) Melanin inhibition rate (%) 0.01 17.12** 0.1 23.56** 1 26.31** 10 27.91** 100 34.32** Nonapeptide-1 25.15** Hexapeptide-2 31.27**

[0167] *: p<0.05, **: p<0.01.

[0168] Compared with the blank control group, the melanin production of B16 cells was significantly reduced after adding 0.01, 0.1, 1, 10 and 100 ppm of NL oligopeptide, respectively, which can be considered to have an inhibitory effect on melanin production. Therefore, the composition containing the oligopeptide in the concentration range of 0.01 to 100 ppm has the effect of preventing or improving skin pigmentation.

[0169] The above effects indicate that the oligopeptide has a melanin production inhibitory effect within a concentration range of 0.01-100 ppm and has an effect of improving skin pigmentation.

[0170] Experimental Example 3

[0171] This experimental example tests the inhibitory effect of oligopeptide modified products on melanin production.

[0172] The inhibitory effect of the N-terminal acetylation modification product of NLPSSP (Example 14), the N-terminal succinylation modification product (Example 15), and the N-terminal palmitoylation modification product (Example 16) on melanin production in B16 cells was evaluated. B16 melanoma cells with good growth status were cultured in a 6-well plate, and 1 ppm of NLPSSP (unmodified group) or each modified product or mutant product of NLPSSP (NLPSSA, NLPSSC, NLPSSD, NLPSSE, NLPSSG, NLPSSH) was added to the blank control group (culture solution) 24 hours later, and then further cultured at 37°C for 48 hours. The inhibitory effect of the oligopeptide on melanin production was detected by the NaOH method, and the results are shown in the following table.

[0173] Inhibitory effect of oligopeptide-modified products on melanin production in B16 cells

[0174] Oligopeptide modified products Melanin inhibition rate (%) Unmodified 29.93** N-acetylated products 28.14** N-succinylated products 31.45** N-palmitoylation products 30.98** NLPSSA 25.31** NLPSSC 23.85** NLPSSD 29.10** NLPSSE 27.37** NLPSSG 28.99** NLPSSH 25.64**

[0175] *: p<0.05, **: p<0.01.

[0176] Compared with the control group, after adding the unmodified group, N-terminal acetylation modification product, N-terminal succinylation modification product, N-terminal palmitoylation modification product or mutant product (NLPSSA, NLPSSC, NLPSSD, NLPSSE, NLPSSG, NLPSSH) of NLPSSP oligopeptide to a final concentration of 1ppm, the melanin production rate of B16 cells was significantly reduced, indicating that it inhibited the melanin production of B16 cells. Therefore, these modified products have the effect of preventing or improving skin pigmentation.

[0177] Experimental Example 4

[0178] This experimental example conducts an experiment to promote the degradation of melanosome membrane by oligopeptides.

[0179] Use DMEM high-glucose medium (Gibco) to culture B16 melanoma cells with good growth in a 6-well plate. After 72 hours, remove the medium, add 5 mL of trypsin EDTA, and let it stand for 20 minutes. Transfer the separated B16 melanoma cells to a 50 mL centrifuge tube, add 5 mL of DMEM containing 10% bovine serum, and centrifuge at 10,000 rpm for 2 minutes to break the cells. Remove the supernatant and transfer the precipitate to a 1.5 mL tube for homogenization. Repeat the operation once. Add 500 μL of human epidermal keratinocyte culture medium ( K Comp kit), centrifuge the cells at 1,000rpm for 2 minutes. Transfer the supernatant to a new 1.5mL test tube and centrifuge at 10,000rpm for 2 minutes. After removing the supernatant, melanosomes were obtained, and epidermal keratinocyte culture fluid was added and repeatedly blown to obtain epidermal keratinocyte culture fluid containing melanosomes. Take 100μL of epidermal keratinocyte culture fluid containing melanosomes and add it to human epidermal keratinocytes that have been cultured in a 6-well plate for 24 hours, then add 1, 10, and 100ppm of oligopeptide YNLL, culture for 72 hours to allow human epidermal keratinocytes to phagocytize the extracted melanosomes, and then use anti-cathepsin L2 antibody (Alexa 546IgG) and DAPI staining to observe the cells. The test results are shown in the following table. The fluorescence intensity of cathepsin L2 and cell nuclei in keratinocytes that have engulfed melanosomes after oligopeptide treatment is shown in the following table.

[0180] Relative fluorescence intensity of cathepsin L2 in keratinocytes that have engulfed melanosomes after oligopeptide treatment.

[0181]

[0182] After comparing the phase fluorescence intensity ratio of cathepsin L2 / DAPI staining, it was found that after treatment with 1, 10, and 100 ppm of oligopeptide YNLL, the expression of cathepsin L2 in human epidermal keratinocytes that had engulfed melanosomes increased by 10.42%, 36.91%, and 136.00%, respectively, while after treatment with 100 ppm of hexapeptide-2 and nonapeptide-1, the expression of cathepsin L2 in human epidermal keratinocytes that had engulfed melanosomes increased by 2.69% and 6.49%, respectively. The fluorescence intensity values ​​are shown in the table, and the increase rate is calculated by the formula: [RFICL2(dose)-RFICL2(blank)] / RFICL2(blank), where RFICL2: L2 relative fluorescence intensity.

[0183] The above results prove that the addition of oligopeptides increases the expression level of cathepsin L2, accelerates the autophagy level of human epidermal keratinocytes, and thus accelerates the degradation of melanosome membranes. In addition, oligopeptides can promote the expression of cathepsin L2 in a concentration-dependent manner, so oligopeptides have the effect of preventing or improving skin pigmentation. In addition, hexapeptide-2 and nonapeptide-1, which are known to have melanin production inhibitory effects, did not show the effect of promoting the phagocytosis of melanosome membranes by human epidermal keratinocytes.

[0184] In summary, the oligopeptides have the effect of promoting the degradation of melanosome membranes, and their effect is better than hexapeptide-2 and nonapeptide-1 in the range of 1-100 ppm.

[0185] Experimental Example 5

[0186] This experimental example is an experiment on the melanin degradation promoting effect of oligopeptides.

[0187] B16 melanoma cells with good growth status were cultured in 6-well plates. After 72 hours, melanosomes were extracted from B16 cells and added to human epidermal keratinocytes cultured in 6-well plates for 24 hours. Then, a blank control group (culture medium), a positive control group hexapeptide-2, nonapeptide-1 (final concentration 100 ppm) or 0.1, 1, 10, 100 ppm of oligopeptide YNLLEDFK were added. After 72 hours of culture, the NaOH method was used to detect the promoting effect of oligopeptides on melanin degradation. The results are shown in the following table.

[0188] Melanin degradation promoting effect of oligopeptides at different concentrations

[0189] Oligopeptide concentration (ppm) Melanin degradation rate (%) 0.1 5.28 1 12.31 10 18.66* 100 25.27** Hexapeptide-2 2.33 Nonapeptide-1 4.15

[0190] Compared with the control group, the degradation rate of melanin in human keratinocytes was significantly increased after adding 10 and 100 ppm of oligopeptide YNLLEDFK, indicating that it promoted the degradation of melanin in human keratinocytes. Therefore, the oligopeptide has the effect of preventing or improving skin pigmentation. However, hexapeptide-2 and nonapeptide-1, which are known to have the effect of inhibiting melanin production, did not show the effect of promoting melanin degradation.

[0191] Embodiment 23

[0192] This embodiment provides an essence composition, which includes phase A, phase B and phase C. The weight ratios of the three phases are shown in the following table. The hydrolyzed conchiolin in phase C is specifically: oligopeptide YNLLEDFK;

[0193]

[0194]

[0195] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. An oligopeptide having melanin inhibitory activity, characterized in that It includes an oligopeptide composed of at least one of the following amino acid sequences: NL, NLP, NLPS, NLPSSP, NLF, YNLF, VLYNLF, YNLFTR, VLDYNLFTR, VLYNLFTR, YNLL and YNLLEDFK, and the oligopeptide has a characteristic sequence: NL; Preferably, the oligopeptide has any one of the following characteristic sequences: NLP, NLF, YNL and YNLF; Preferably, the oligopeptide comprises an oligopeptide composed of at least one of the following amino acid sequences: NL, NLPS, NLPSSP, YNLL, YNLLEDFK.

2. An oligopeptide having melanin inhibitory activity, characterized in that The oligopeptide has a characteristic sequence: NL, and the amino acid sequence of the oligopeptide is a sequence obtained by mutation of a single amino acid in any of the following amino acid sequences: NL, NLP, NLPS, NLPSSP, NLF, YNLF, VLYNLF, YNLFTR, VLDYNLFTR, VLYNLFTR, YNLL and YNLLEDFK; Preferably, the amino acid sequence of the mutated oligopeptide is selected from NLPSSA, NLPSSC, NLPSSD, NLPSSE, NLPSSG and NLPSSH; Preferably, the oligopeptide has any one of the following characteristic sequences: NLP, NLF, YNL and YNLF.

3. An oligopeptide having melanin inhibitory activity, characterized in that The oligopeptide has a characteristic sequence: NL, and the oligopeptide includes an oligopeptide composed of at least one of the following amino acid sequences, and at least one amino acid in the oligopeptide is modified: NL, NLP, NLPS, NLPSSP, NLF, YNLF, VLYNLF, YNLFTR, VLDYNLFTR, VLYNLFTR, YNLL and YNLLEDFK; Preferably, the oligopeptide has any one of the following characteristic sequences: NLP, NLF, YNL and YNLF; Preferably, the oligopeptide comprises an oligopeptide composed of at least one of the following amino acid sequences: NL, NLPS, NLPSSP, YNLL, YNLLEDFK; Preferably, the modification is selected from at least one of glycosylation modification, phosphorylation modification, ubiquitination modification, S-nitrosylation modification, methylation modification, hydroxylation modification and acylation modification; Preferably, the methylation modification is selected from at least one of N-methylation modification and O-methylation modification; Preferably, the acylation modification is selected from at least one of acetylation modification, amidation modification, nicotinoylation modification, palmitoylation modification, succinylation modification, acryloylation modification and myristoylation modification; Preferably, the acylation modification is selected from at least one of N-terminal nicotinoylation modification, N-acetylation modification, N-palmitoylation modification, N-succinylation modification, N-myristoylation modification and C-amidation modification.

4. A tandem protein, characterized in that The amino acid sequence of the tandem protein is formed by repeated tandem connection of n active oligopeptides, wherein n is a natural number greater than 1, and the oligopeptide is an oligopeptide with melanin inhibitory activity as shown in claim 1, 2 or 3; Preferably, n is selected from any value between 2 and 5.

5. Use of the oligopeptide with melanin inhibitory activity as claimed in claim 1, 2 or 3 or the tandem protein as claimed in claim 4 in the preparation of a melanin production inhibitory product.

6. Use of the oligopeptide with melanin inhibitory activity as claimed in claim 1, 2 or 3 or the tandem protein as claimed in claim 4 in the preparation of a product for degrading melanosome membranes; Preferably, the application of degrading melanosome membranes includes at least one of the following application modes: (1) Increase the expression level of cathepsin; (2) Accelerate autophagy of human epidermal keratinocytes.

7. Use of the oligopeptide with melanin inhibitory activity as claimed in claim 1, 2 or 3 or the tandem protein as claimed in claim 4 in the preparation of a product promoting melanin degradation.

8. Use of the oligopeptide with melanin inhibitory activity as claimed in claim 1, 2 or 3 or the tandem protein as claimed in claim 4 in the preparation of a product for preventing, alleviating or improving pigmentation.

9. The use according to claim 5, 6, 7 or 8, characterized in that The product is a medicine, a cosmetic, a skin care product or a food.

10. A composition, characterized in that The composition comprises the active ingredient of any one of (1) and (2): (1) comprising the oligopeptide with melanin inhibitory activity as described in claim 1, 2 or 3 or the tandem protein as described in claim 4; (2) comprising the oligopeptide with melanin inhibitory activity as described in claim 1, 2 or 3 or the tandem protein as described in claim 4; Preferably, the content of the active ingredient in the composition is 0.01-100 ppm; Preferably, the content of the active ingredient in the composition is 1-100 ppm; Preferably, the composition further comprises an auxiliary material.

Citation Information

Patent Citations

  • Pearl-derived polypeptide with multiple skin activities and application thereof

    CN116807918A

Cited By

  • Preparation method of nonapeptide-1

    CN119912522A

  • A preparation method of nonapeptide-1

    CN119912522B

  • Hydrolyzed conchiolin protein as well as preparation method and application thereof

    CN120944998A